News
Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status
Affinivax and Astellas’ pneumococcal vaccine candidate ASP3772 has been granted a breakthrough therapy designation by the US Food and Drug Administration (FDA), the companies announced earlier this week.